BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdullah KG, Bird CE, Buehler JD, Gattie LC, Savani MR, Sternisha AC, Xiao Y, Levitt MM, Hicks WH, Li W, Ramirez DMO, Patel T, Garzon-Muvdi T, Barnett S, Zhang G, Ashley DM, Hatanpaa KJ, Richardson TE, McBrayer SK. Establishment of patient-derived organoid models of lower grade glioma. Neuro Oncol 2021:noab273. [PMID: 34850183 DOI: 10.1093/neuonc/noab273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie X, Li X, Song W. Tumor organoid biobank-new platform for medical research. Sci Rep 2023;13:1819. [PMID: 36725963 DOI: 10.1038/s41598-023-29065-2] [Reference Citation Analysis]
2 Ferrarese R, Izzo A, Andrieux G, Lagies S, Bartmuss JP, Masilamani AP, Wasilenko A, Osti D, Faletti S, Schulzki R, Yuan S, Kling E, Ribecco V, Heiland DH, Tholen S, Prinz M, Pelicci G, Kammerer B, Boerries M, Carro MS. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma. Life Sci Alliance 2023;6:e202201400. [DOI: 10.26508/lsa.202201400] [Reference Citation Analysis]
3 Riedel NC, de Faria FW, Alfert A, Bruder JM, Kerl K. Three-Dimensional Cell Culture Systems in Pediatric and Adult Brain Tumor Precision Medicine. Cancers (Basel) 2022;14. [PMID: 36497454 DOI: 10.3390/cancers14235972] [Reference Citation Analysis]
4 Wang Y, Duan J. Modeling nervous system tumors with human stem cells and organoids.. [DOI: 10.21203/rs.3.rs-1820434/v1] [Reference Citation Analysis]
5 Ma C, Seong H, Li X, Yu X, Xu S, Li Y, Chimenti I. Human Brain Organoid: A Versatile Tool for Modeling Neurodegeneration Diseases and for Drug Screening. Stem Cells International 2022;2022:1-20. [DOI: 10.1155/2022/2150680] [Reference Citation Analysis]
6 Anastasaki C, Chatterjee J, Cobb O, Sanapala S, Scheaffer SM, De Andrade Costa A, Wilson AF, Kernan CM, Zafar AH, Ge X, Garbow JR, Rodriguez FJ, Gutmann DH. Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling. acta neuropathol commun 2022;10. [DOI: 10.1186/s40478-022-01428-2] [Reference Citation Analysis]
7 Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin YF, Puliyappadamba VT, Gao W, Khanal J, Evans L, Lee JH, Guo L, Xiao Y, Xu M, Huang B, Jennings RB, Bonal DM, Martin-Sandoval MS, Dang T, Gattie LC, Cameron AB, Lee S, Asara JM, Kornblum HI, Mak TW, Looper RE, Nguyen QD, Signoretti S, Gradl S, Sutter A, Jeffers M, Janzer A, Lehrman MA, Zacharias LG, Mathews TP, Losman JA, Richardson TE, Cahill DP, DeBerardinis RJ, Ligon KL, Xu L, Ly P, Agar NYR, Abdullah KG, Harris IS, Kaelin WG Jr, McBrayer SK. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell 2022:S1535-6108(22)00324-5. [PMID: 35985343 DOI: 10.1016/j.ccell.2022.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-Mendelewska E, Brok M, DeMartino J, Manders F, Calandrini C, Kerstens HHD, Janse A, Dolman MEM, Eising S, Langenberg KPS, van Tuil M, Knops RRG, van Scheltinga ST, Hiemcke-Jiwa LS, Flucke U, Merks JHM, van Noesel MM, Tops BBJ, Hehir-Kwa JY, Kemmeren P, Molenaar JJ, van de Wetering M, van Boxtel R, Drost J, Holstege FCP. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Mol Med 2022;:e16001. [PMID: 35916583 DOI: 10.15252/emmm.202216001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hicks WH, Bird CE, Gattie LC, Shami ME, Traylor JI, Shi DD, Mcbrayer SK, Abdullah KG. Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer. Curr Stem Cell Rep. [DOI: 10.1007/s40778-022-00211-2] [Reference Citation Analysis]
10 Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-mendelewska E, Brok M, Demartino J, Manders F, Calandrini C, Kerstens HHD, Janse A, Dolman MEM, Eising S, Langenberg KPS, van Tuil M, Knops RRG, van Scheltinga ST, Hiemcke-jiwa LS, Flucke U, Merks JHM, van Noesel MM, Tops BBJ, Hehir-kwa JY, Kemmeren P, Molenaar JJ, van de Wetering M, van Boxtel R, Drost J, Holstege FCP. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.. [DOI: 10.1101/2022.01.03.474504] [Reference Citation Analysis]
11 Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin Y, Gao W, Khanal J, Xu M, Huang B, Jennings RB, Bonal DM, Martin-sandoval MS, Dang T, Gattie LC, Lee S, Asara JM, Kornblum HI, Mak TW, Looper RE, Nguyen Q, Signoretti S, Gradl S, Sutter A, Jeffers M, Janzer A, Lehrman MA, Zacharias LG, Mathews TP, Richardson TE, Cahill DP, Deberardinis RJ, Ligon KL, Ly P, Agar NYR, Abdullah KG, Harris IS, Kaelin WG, Mcbrayer SK. De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma.. [DOI: 10.1101/2021.11.30.470443] [Reference Citation Analysis]